Neonc Technologies (NASDAQ:NTHI) Upgraded at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Neonc Technologies (NASDAQ:NTHI – Free Report) from a strong sell rating to a sell rating in a report published on Sunday morning,Wall Street Zen reports.

NTHI has been the subject of a number of other reports. BTIG Research reaffirmed a “buy” rating and set a $15.00 price target on shares of Neonc Technologies in a report on Tuesday, September 8th. Zacks Research lowered Neonc Technologies from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 7th. Roth Capital began coverage on Neonc Technologies in a report on Thursday, September 24th. They issued a “buy” rating on the stock. Finally, Weiss Ratings upgraded Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, October 6th. Four research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $16.00.

View Our Latest Report on NTHI

Neonc Technologies Stock Up 1.8%

Shares of Neonc Technologies stock opened at $2.77 on Friday. The firm’s 50-day moving average price is $3.70 and its two-hundred day moving average price is $4.30. Neonc Technologies has a 1-year low of $2.50 and a 1-year high of $12.00.

Neonc Technologies (NASDAQ:NTHI – Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

Insider Activity at Neonc Technologies

In other Neonc Technologies news, CEO Thomas C. Chen bought 12,757 shares of the stock in a transaction on Tuesday, August 18th. The stock was purchased at an average price of $5.49 per share, with a total value of $70,035.93. Following the acquisition, the chief executive officer owned 13,705 shares of the company’s stock, valued at approximately $75,240.45. The trade was a 1,345.68% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Amir F. Heshmatpour bought 37,000 shares of the company’s stock in a transaction on Friday, September 11th. The shares were acquired at an average price of $3.67 per share, with a total value of $135,790.00. Following the transaction, the chief executive officer directly owned 3,133,000 shares in the company, valued at approximately $11,498,110. The trade was a 1.20% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 134,812 shares of company stock worth $530,149 over the last 90 days.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in NTHI. Bank of America Corp DE grew its stake in shares of Neonc Technologies by 5.0% during the first quarter. Bank of America Corp DE now owns 235,396 shares of the company’s stock worth $1,650,000 after purchasing an additional 11,108 shares during the period. Westmount Partners LLC increased its holdings in Neonc Technologies by 355.2% in the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock valued at $893,000 after purchasing an additional 153,858 shares during the last quarter. BlackRock Inc. bought a new stake in Neonc Technologies in the second quarter valued at about $815,000. Finally, Global Retirement Partners LLC bought a new stake in Neonc Technologies in the second quarter valued at about $126,000.

Neonc Technologies Company Profile

(Get Free Report)

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

Read More